Don't cut lifesaving ICDs during financial crisis, ESC warns

August 29, 2012

Implantable devices for treating cardiac arrhythmias, which include ICDs, are already underused in parts of Eastern and Central Europe and there is a risk that the financial crisis could exacerbate the problem. The European Heart Rhythm Association (EHRA), a registered branch of the ESC, is tackling this issue through ICD for Life. The initiative aims to raise awareness about the importance of ICDs and sudden cardiac death in countries in Central and Eastern Europe.

ICD implantation rates in Europe vary widely, ranging from 1 ICD implantation per million inhabitants in Ukraine to 326 in Germany. Treatment gaps between East and West exist for other cardiovascular implantable electronic devices (CIEDs) including implantable pulse generators (IPGs, also called ) and (CRT) devices.

"This is becoming challenging in a day where the is shrinking and Europe is even more under pressure now," said Professor Angelo Auricchio (Switzerland), president of EHRA. "Usually the first things that are cut in the national budgets across Europe are implantable therapies because they are a long term investment. You have to implant an expensive device for which the return will be seen in 4 to 10 years."

He added: "I'm very afraid that in the bad European it will become even more challenging to properly treat patients who need . With our initiative we hope to raise awareness about the importance of implantable devices and sudden cardiac death so that cash strapped governments do not cut these very important and proven therapies."

An EHRA ICD for Life Summit will be held in Belgrade, Serbia, during 19-20 October, to discuss challenges and unmet needs in Central and Eastern European countries. The Summit is targeted at politicians, , policy makers, representatives of , arrhythmologists and electrophysiologists. The president of the Summit Organizing Committee is Professor Goran Milasinovic (Serbia), who pioneered the ICD for Life idea.

"Our aim is to convince the decision makers that this is a part of cardiology which needs better financing, and that they will get a return on their investment in terms of decreasing mortality," said Professor Robert Hatala (Slovakia), chair of the EHRA National Societies Committee. "The scientific evidence that these therapies are not a luxury but a highlyefficient therapy with no alternatives is very powerful."

An expected outcome of the Summit is that each country will identify its own obstacles to treating patients with CIEDs and catheter ablation,. EHRA will then help with solutions, which may include training doctors to implant devices and perform catheter ablation. Central European countries, primarily Czech Republic, Hungary, Poland, and Slovakia, who have successfully established arrhythmia programmes under difficult conditions in the last 10-15 years will provide mentoring , hands on training and on-site support.

The Summit will also launch the idea of a Sudden Cardiac Death Awareness Day, which will be held during December 2012 or January 2013. National working groups of arrhythmia and electrophysiology in Central and Eastern Europe will choose the best way of raising awareness of arrhythmias and sudden cardiac death in their country to increase rates of treatment and reduce death. EHRA will award a prize to the country that runs the most successful awareness day.

Professor Auricchio said: "We hope to capture the attention of patients, patient organisations, policy makers and insurance companies and help them understand that sudden cardiac death is an important problem which needs to be solved, because we do have effective therapies."

There are misconceptions surrounding . A commonly held view amongst the public is that sudden cardiac deaths are the result of a heart attack, but they are usually caused by such as ventricular tachycardia. These electrical disorders can be treated with CIEDs. Professor Hatala said: "We want to highlight that we can identify some people who are at very high risk of dying suddenly and that these people need urgently specific therapy."

Explore further: Gene variant may predict sudden cardiac death risk for blacks

Related Stories

Gene variant may predict sudden cardiac death risk for blacks

May 11, 2011
(Medical Xpress) -- Researchers at Duke University Medical Center have pinpointed a common gene variant in blacks that may be associated with the development of life-threatening heart arrhythmias. The finding may help determine ...

Top cardiac electrophysiology congresses join forces

June 13, 2012
Nice, 13 June 2012: Europe's leading congresses in cardiac electrophysiology have agreed to hold a joint annual Congress during 2014-2017. The official agreement was signed by ESC-EHRA and CARDIOSTIM-REED on 13 June, during ...

Recommended for you

Young diabetics could have seven times higher risk for sudden cardiac death

December 12, 2017
Young diabetics could have seven times more risk of dying from sudden cardiac arrest than their peers who don't have diabetes, according to new research.

Ultra-thin tissue samples could help to understand and treat heart disease

December 12, 2017
A new method for preparing ultra-thin slices of heart tissue in the lab could help scientists to study how cells behave inside a beating heart.

Blood flow–sensing protein protects against atherosclerosis in mice

December 12, 2017
UCLA scientists have found that a protein known as NOTCH1 helps ward off inflammation in the walls of blood vessels, preventing atherosclerosis—the narrowing and hardening of arteries that can cause heart attacks and strokes. ...

Half of people aged 40-54 have hardened arteries: study

December 11, 2017
Half of middle-aged people who are normal weight and don't smoke or have diabetes may have clogged arteries, researchers said Thursday, urging stronger measures to lower cholesterol.

Research suggests new pathways for hyperaldosteronism

December 7, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with researchers at Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the ...

One-dose gene therapy produces clotting factor, safely stops bleeding in hemophilia B patients

December 6, 2017
A team of gene therapy researchers has reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. A single intravenous infusion of a novel bioengineered gene therapy treatment ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.